drugset
drugset / Trial / NCT03696459

A Study to Evaluate the Effect of JNJ-53718678 on the Cardiac Repolarization Interval in Healthy Adult Participants

NCT03696459 ↗

Phase 1 Completed 52 enrolled Janssen Research & Development, LLC
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of this study is to assess the effect of JNJ-53718678 on QT interval corrected for heart rate (QTc) changes using exposure response analysis in healthy adult participants (Part 2).

Timeline

Start
2018-10-02
Primary completion
2019-12-13
Completion
2019-12-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxifloxacin Small molecule 400 mg Oral
Subject Rilematovir Other / unclassified 500 mg Oral
Subject Rilematovir Other / unclassified 2000 mg Oral
Subject Rilematovir Other / unclassified 3000 mg Oral
Subject Rilematovir Other / unclassified 4500 mg Oral

Indications

No indication recorded.